Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Mylan Counts On A Renaissance For Expansion

Executive Summary

European markets are the name of the game as Ariad sells its European business to Incyte, Spain's Grupo Ferrer buys out Alexza, Italy's Chiesi bags a suite of CV drugs from The Medicines Co. and Swiss kidney disease specialist Vifor Fresenius takes up Opko's Rayaldee.

You may also be interested in...



Mylan Confident On Advair Generic First-Round Approval

President Rajiv Malik said there has been “huge movement” at the agency around executing on the first ANDA for a generic version of GlaxoSmithKline’s blockbuster Advair.

Mylan Finally Nabs Meda In Diversification Play

Deal coincides with full year/fourth quarter earnings release.

Five-Plus-Five Equals A Focus On Execution At Lilly In 2023

Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel